非血管用ステント市場：製品タイプ、材料タイプ、用途、地域別、2026年～2032年

非血管用ステント市場の評価、2026年～2032年

胆道疾患、消化器疾患、泌尿器疾患など、ステント留置術を必要とする慢性疾患の有病率は増加しています。人口の高齢化に伴い、これらの疾患の有病率は増加し、非血管用ステント留置術のような効果的な治療オプションの必要性が高まっています。技術の進歩も、生分解性ステントや薬剤溶出性ステントなどの革新的なステント設計の開発に重要な役割を果たしており、再狭窄や移動などの合併症のリスクを低下させながら患者の予後を改善することで、2024年には12億1,000万米ドルを超え、2032年には17億1,000万米ドルに達する市場の成長を牽引しています。

さらに、低侵襲手術への嗜好の高まりが非血管用ステントの使用を加速させており、これは従来の手術法よりも回復時間が短く、リスクも低いです。これらの要因が相まって、非血管用ステントに対する需要が高まっており、2026年から2032年までのCAGRは約4.80%で市場のさらなる成長が見込まれています。

非血管用ステント市場定義/概要

非血管用ステントは、胆管、尿管、食道、腸などの非血管臓器にある管や通路を開通または閉塞解除する医療機器です。主な用途は、これらの臓器の自然な流れを阻害する閉塞、狭窄、腫瘍などの状態を治療することであり、消化器、泌尿器、呼吸器医療において重要な解決策を提供します。非血管用ステントの将来は、生分解性ステントや薬剤溶出性ステントのようなステント材料やデザインの進歩により、患者の転帰を改善し、合併症を減らし、より幅広い臨床用途での使用を拡大することが期待されるため、有望視されています。慢性疾患の有病率が上昇し続けるにつれて、こうした低侵襲治療の需要は増大し、非血管用ステントはますます現代ヘルスケアに不可欠な要素になっていくでしょう。

慢性疾患の増加は非血管用ステント市場を牽引するか？

慢性疾患の罹患率の上昇は、非血管用ステント市場の主な促進要因です。胆道疾患、消化器疾患、泌尿器疾患などの慢性疾患では、管や通路を開いた状態に保つためにステント留置術が必要になることが多いです。こうした疾患が特に高齢者層で一般的になるにつれて、非血管用ステントの需要は増加すると予想されます。例えば、胆石や腫瘍による胆管閉塞などの胆道疾患の増加により、閉塞を緩和して患者の予後を改善するために胆道ステントを使用する必要があります。

2024年10月、ボストン・サイエンティフィック社は、良性胆道狭窄治療用の新しい完全被覆型金属ステントの導入を発表しました。これは、ステントの性能と患者の安全性の向上を目指した継続的な技術革新を反映したものです。このような技術進歩は、ステントの有効性を向上させるだけでなく、さまざまな慢性疾患への適用を拡大し、市場の成長を促進します。

2024年6月、FDAは新しい薬剤溶出性食道ステントを承認し、食道がん患者に新たな治療選択肢を提供しました。この承認は、先進的なステント技術に対する規制当局の支持が高まっていることを示しており、この分野のさらなる研究開発に拍車がかかることが期待されます。政府やヘルスケア機関が慢性疾患の治療を優先し続ける中、非血管用ステント市場は今後数年で安定した成長が見込まれます。

感染合併症リスクの上昇は非血管用ステント市場の妨げになるか？

合併症、特に感染症のリスク上昇は、非血管用ステント市場の成長を阻害する可能性のある大きな懸念材料です。ステント留置に伴う感染症は、入院期間の延長、手術の追加、ヘルスケアコストの増加など、患者に深刻な結果をもたらす可能性があるため、深刻な懸念となっています。このような合併症を恐れるあまり、医師も患者もステントを用いた治療を選択しなくなり、市場の潜在的な成長が制限される可能性があります。

さらに、感染のリスクは非血管用ステントの評判や使用に影響を与える可能性があります。感染リスクが高まれば、特に脆弱な患者集団では、ヘルスケアプロバイダーがステント治療を勧めることに慎重になる可能性があります。このような慎重なアプローチは、感染リスクを低減するためのデザインや材料の進歩にもかかわらず、新しいステント技術の採用を遅らせる可能性があります。

こうした直接的な影響に加え、感染症などの合併症リスクの増大は、新しいステント製品の承認に対する規制要件の厳格化につながる可能性があります。このため、新しいステントを市場に投入するまでの時間とコストが増大し、市場の成長が阻害される可能性があります。その結果、メーカー各社は、費用対効果に優れ、幅広い患者が利用可能でありながら、こうしたリスクを軽減できる革新的なステントを開発・販売する上で困難に直面する可能性があります。

目次

第1章 イントロダクション

• 市場の定義
• 市場セグメンテーション
• 調査手法

第2章 エグゼクティブサマリー

• 主な調査結果
• 市場概要
• 市場ハイライト

第3章 市場概要

• 市場規模と成長の可能性
• 市場動向
• 市場促進要因
• 市場抑制要因
• 市場機会
• ポーターのファイブフォース分析

第4章 非血管用ステント市場：製品タイプ別

• 消化器用ステント
• 泌尿器ステント
• 肺ステント
• 胆道ステント
• 膵臓ステント

第5章 非血管用ステント市場：材料タイプ別

• 金属ステント
• プラスチック/ポリマー製ステント
• 生分解性ステント
• ハイブリッドステント

第6章 非血管用ステント市場：用途別

• 消化器疾患
• 泌尿器疾患
• 肺疾患
• 胆道疾患
• 膵臓疾患

第7章 地域分析

• 北米
• 米国
• カナダ
• メキシコ
• 欧州
• 英国
• ドイツ
• フランス
• イタリア
• アジア太平洋
• 中国
• 日本
• インド
• オーストラリア
• ラテンアメリカ
• ブラジル
• アルゼンチン
• チリ
• 中東・アフリカ
• 南アフリカ
• サウジアラビア
• アラブ首長国連邦

第8章 市場力学

• 市場促進要因
• 市場抑制要因
• 市場機会
• COVID-19の市場への影響

第9章 競合情勢

• 主要企業
• 市場シェア分析

第10章 企業プロファイル

• Becton, Dickinson and Company（BD）
• Boston Scientific Corporation
• CONMED Corporation
• Cook Medical
• ELLA-CS, s.r.o.
• Glaukos Corporation
• Medtronic
• Micro-Tech（Nanjing）Co., Ltd.
• Merit Medical Systems

第11章 市場の展望と機会

• 新興技術
• 今後の市場動向
• 投資機会

第12章 付録

• 略語リスト
• 出典と参考文献

Non Vascular Stents Market Valuation - 2026-2032

The prevalence of chronic diseases requiring stenting procedures, such as biliary, gastrointestinal, and urological disorders, is increasing. As populations age, the prevalence of these conditions increases, necessitating a greater need for effective treatment options such as non-vascular stenting. Technological advancements have also played an important role in the development of innovative stent designs, such as biodegradable and drug-eluting stents, which improve patient outcomes while lowering the risk of complications such as restenosis and migration driving the market growth surpassing USD 1.21 Billion in 2024 and reaching USD 1.71 Billion by 2032.

Furthermore, the growing preference for minimally invasive procedures has accelerated the use of non-vascular stents, which are associated with shorter recovery times and lower risks than traditional surgical methods. Together, these factors are driving demand for non-vascular stents, positioning the market for further growth is expected to grow at a CAGR of about 4.80% from 2026 to 2032.

Non Vascular Stents Market: Definition/ Overview

Non-vascular stents are medical devices that open or unblock ducts and passageways in non-vascular organs such as the bile ducts, ureters, esophagus, and intestines. Their primary use is to treat conditions such as obstructions, strictures, and tumors that obstruct the natural flow of these organs, providing an important solution in gastrointestinal, urological, and respiratory medicine. The future of non-vascular stents looks promising, thanks to advances in stent materials and designs like biodegradable and drug-eluting stents, which are expected to improve patient outcomes, reduce complications, and expand their use in broader clinical applications. As the prevalence of chronic diseases continues to rise, the demand for these minimally invasive treatments will grow, making non-vascular stents an increasingly vital component of modern healthcare.

Will Increasing Prevalence of Chronic Diseases Drive the Non Vascular Stents Market?

The rising incidence of chronic diseases is a major driver of the non-vascular stents market. Chronic conditions such as biliary, gastrointestinal, and urological disorders frequently necessitate stenting procedures to keep ducts and passageways open. As these diseases become more common, particularly in older populations, the demand for non-vascular stents is expected to rise. For example, the increasing prevalence of biliary diseases, such as bile duct obstruction caused by gallstones or tumours, necessitates the use of biliary stents to relieve blockages and improve patient outcomes.

In October 2024, Boston Scientific announced the introduction of a new fully covered metal stent for the treatment of benign biliary strictures, reflecting ongoing innovation aimed at improving stent performance and patient safety. Such technological advancements not only improve the efficacy of stents, but also broaden their application to a variety of chronic conditions, driving market growth.

In June 2024, the FDA approved a new drug-eluting esophageal stent, providing a novel treatment option for patients with esophageal cancer. This approval demonstrates the growing regulatory support for advanced stent technologies, which is expected to spur additional research and development in the field. As governments and healthcare organizations continue to prioritize the treatment of chronic diseases, the non-vascular stents market is expected to grow steadily in the coming years.

Will Rising Risk of Complications of Infection Hamper the Non Vascular Stents Market?

The rising risk of complications, particularly infections, is a major concern that may impede the growth of the non-vascular stents market. Infections associated with stent placement are a serious concern because they can have serious consequences for patients, such as longer hospital stays, additional surgeries, and higher healthcare costs. The fear of such complications may deter both physicians and patients from choosing stent-based treatments, limiting the market's potential growth.

Furthermore, the risk of infection can have an impact on the reputation and use of non-vascular stents. Healthcare providers may be more cautious about recommending stent procedures if infection risks are increased, particularly in vulnerable patient populations. This cautious approach may slow the adoption of new stent technologies, despite advancements in design and materials to reduce infection risks.

In addition to these direct consequences, the increased risk of complications such as infection may lead to stricter regulatory requirements for the approval of new stent products. This could increase the time and cost of bringing new stents to market, stifling market growth. As a result, manufacturers may face difficulties in developing and marketing innovative stents that can mitigate these risks while remaining cost-effective and accessible to a wide range of patients.

Category-Wise Acumens

Will Rising Demand of Gastrointestinal Stents Propel the Non Vascular Stents Market?

The increasing demand for gastrointestinal stents is expected to significantly boost the non-vascular stents market. Gastrointestinal stents are critical for managing a variety of conditions, including esophageal strictures, gastrointestinal obstructions, and tumors, all of which are becoming more common as the population ages and chronic diseases such as cancer become more prevalent. The growing demand for effective solutions in these areas is resulting in the dominance of gastrointestinal stents, driving market growth.

In March 2024, Medtronic announced the release of an advanced esophageal stent, with the goal of improving patient outcomes through increased durability. This development reflects ongoing innovation aimed at improving the efficacy and safety of gastrointestinal stents in response to rising demand caused by complex medical conditions. Such innovations not only broaden the market, but also increase the popularity of gastrointestinal stents in clinical practice.

For instance, in July 2024, the US FDA granted expedited approval for a new biodegradable stent intended for use in the GI tract. This regulatory endorsement emphasizes the commitment to improving treatment options for gastrointestinal disorders and encourages wider use of stents. As healthcare policies prioritize advanced treatment technologies, the non-vascular stents market is expected to expand further, driven by rising demand for gastrointestinal stents.

However, the urological stents segment is expected to grow at the fastest rate. This expansion is fueled by the rising prevalence of urological disorders such as kidney stones and benign prostatic hyperplasia (BPH). The rising prevalence of these conditions, combined with advances in stent technology that improve patient outcomes and reduce complications, is driving the rapid growth of the urological stents market.

Will Rising Usage of Metal Stents Drive the Non Vascular Stents Market?

The increasing use of metal stents is expected to fuel significant growth in the non-vascular stents market. Metal stents, which are known for their durability and structural integrity, are used to treat a variety of non-vascular conditions, including biliary obstructions and esophageal strictures. Their ability to provide long-term support and keep ducts and passageways open has made them a popular choice among clinicians, resulting in increased demand and market expansion.

In August 2024, the European Medicines Agency (EMA) approved a new generation of metal stents with advanced features for gastrointestinal use. This regulatory approval demonstrates the industry's commitment to improving stent technology and encouraging wider adoption. As regulatory bodies continue to support innovative solutions and address clinical needs, the non-vascular stents market is expected to benefit from increased use of metal stents, owing to their proven efficacy and technological advancements.

Biodegradable stents are the fastest growing segment. This rapid growth is driven by their innovative design, which overcomes the limitations of traditional stents by gradually dissolving in the body, lowering the risk of long-term complications and the need for additional procedures. The growing emphasis on patient safety and the demand for minimally invasive solutions are driving the adoption of biodegradable stents, making them a key market growth opportunity.

Country/Region-wise

Will Increasing Advanced Healthcare Infrastructure in North America Drive the Non Vascular Stents Market?

The expanding advanced healthcare infrastructure in North America is expected to drive significant growth in the non-vascular stents market. The region's robust healthcare system, which includes cutting-edge medical facilities, comprehensive patient care, and high levels of healthcare spending, encourages the widespread use of advanced medical technologies, such as non-vascular stents. Enhanced infrastructure enables the integration of cutting-edge stent technologies and gives patients access to sophisticated treatments that improve outcomes for a variety of non-vascular conditions.

Furthermore, industry advancements help to drive growth. In July 2024, Medtronic unveiled its new series of non-vascular stents, with research and development supported by the region's advanced healthcare infrastructure. This release emphasizes the importance of sophisticated healthcare environments in the development and distribution of medical technologies. As North America continues to dominate owing to investment and expanding healthcare capabilities, the non-vascular stents market is expected to grow, owing to increased access to and use of advanced medical devices.

Will Rising Awareness of Advanced Treatment Options in Asia-Pacific Propel the Non Vascular Stents Market?

Rising awareness of advanced treatment options in Asia-Pacific is expected to enable the region witness rapid growth in the non-vascular stents market. As the region's healthcare systems evolve and improve, more patients and providers are becoming aware of the advantages and accessibility of advanced medical devices such as non-vascular stents. This increased awareness is driving increased adoption of these devices, as more people seek cutting-edge treatments for conditions like gastrointestinal obstructions, urological issues, and pulmonary disorders.

In March 2024, the Indian Ministry of Health launched a national campaign to educate healthcare professionals and the public about advanced treatment technologies, such as non-vascular stents. This initiative is part of a larger effort to improve healthcare outcomes and give patients access to the most recent medical innovations. Such campaigns are critical for closing the knowledge gap and encouraging the use of advanced treatment options throughout the region.

In April 2024, Olympus Corporation introduced a new line of non-vascular stents designed specifically for the Asia-Pacific market, with innovative designs that address regional healthcare needs. This move reflects the growing demand for sophisticated medical solutions, which is driven by increased awareness and access to healthcare. As education and technology advance, the non-vascular stents market in Asia-Pacific is expected to expand significantly, driven by increased patient awareness and improved healthcare infrastructure.

Competitive Landscape

The competitive landscape of the non-vascular stents market is characterized by a mix of established companies and emerging players focusing on innovation and expanding their product portfolios. Companies are investing in R&D to develop stents with improved materials, flexibility, and biocompatibility to meet the specific needs of various non-vascular applications, such as biliary, esophageal, and ureteral stenting. Additionally, strategic partnerships, acquisitions, and regional expansions are common strategies as companies aim to enhance their market presence and reach. The market is also witnessing an increase in the adoption of minimally invasive procedures, further driving competition among manufacturers.

Some of the prominent players operating in the non vascular stents market include:

Becton

Dickinson and Company (BD)

Boston Scientific Corporation

CONMED Corporation

Cook Medical

ELLA-CS s.r.o.

Medtronic

Micro-Tech (Nanjing) Co. Ltd.

Merit Medical Systems

Latest Developments

In June 2024, The FDA approved their latest biliary stent, which has increased flexibility and anti-migration properties. This new product aims to increase patient comfort while reducing the need for repeat procedures.

In May 2024, Cook Medical introduced a new line of esophageal stents designed for easier placement and less tissue irritation. The stents are expected to gain popularity in treating both malignant and benign esophageal strictures.

In August 2024, Merit Medical Systems announced the acquisition of a smaller stent manufacturer, which will broaden their portfolio of gastroenterology products and increase their non-vascular stent market share.

In September 2024, Taewoong Medical has signed a distribution agreement with a major European medical device company to expand the reach of their non-vascular stents throughout Europe, with a focus on the esophageal and biliary stent markets.

Non Vascular Stents Market, By Category

• Product Type:
• Gastrointestinal Stents
• Urological Stents
• Pulmonary Stents
• Biliary Stents
• Pancreatic Stents
• Material Type:
• Metal Stents
• Plastic/Polymer Stents
• Biodegradable Stents
• Hybrid Stents
• Application:
• Gastrointestinal Disorders
• Urological Disorders
• Pulmonary Disorders
• Biliary Disorders
• Pancreatic Disorders
• Region:
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa

TABLE OF CONTENTS

1. Introduction

• Market Definition
• Market Segmentation
• Research Methodology

2. Executive Summary

• Key Findings
• Market Overview
• Market Highlights

3. Market Overview

• Market Size and Growth Potential
• Market Trends
• Market Drivers
• Market Restraints
• Market Opportunities
• Porter's Five Forces Analysis

4. Non-Vascular Stents Market, By Product Type

• Gastrointestinal Stents
• Urological Stents
• Pulmonary Stents
• Biliary Stents
• Pancreatic Stents

5. Non-Vascular Stents Market, By Material Type

• Metal Stents
• Plastic/Polymer Stents
• Biodegradable Stents
• Hybrid Stents

6. Non-Vascular Stents Market, By Application

• Gastrointestinal Disorders
• Urological Disorders
• Pulmonary Disorders
• Biliary Disorders
• Pancreatic Disorders

7. Regional Analysis

• North America
• United States
• Canada
• Mexico
• Europe
• United Kingdom
• Germany
• France
• Italy
• Asia-Pacific
• China
• Japan
• India
• Australia
• Latin America
• Brazil
• Argentina
• Chile
• Middle East and Africa
• South Africa
• Saudi Arabia
• UAE

8. Market Dynamics

• Market Drivers
• Market Restraints
• Market Opportunities
• Impact of COVID-19 on the Market

9. Competitive Landscape

• Key Players
• Market Share Analysis

10. Company Profiles

• Becton, Dickinson and Company (BD)
• Boston Scientific Corporation
• CONMED Corporation
• Cook Medical
• ELLA-CS, s.r.o.
• Glaukos Corporation
• Medtronic
• Micro-Tech (Nanjing) Co., Ltd.
• Merit Medical Systems

11. Market Outlook and Opportunities

• Emerging Technologies
• Future Market Trends
• Investment Opportunities

12. Appendix

• List of Abbreviations
• Sources and References